MYCOSIS FUNGOIDES
Clinical trials for MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells get a navigation system to hunt down lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with certain types of lymphoma that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells, plus a…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:15 UTC
-
New drug shows promise for controlling rare skin cancers
Disease control OngoingThis study tests a drug called brentuximab vedotin in 79 people with CD30-positive skin lymphomas (a type of cancer). The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 weeks, and researchers track how many respond and how long …
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
New combo therapy for rare skin cancer shows early promise
Disease control TerminatedThis study tests whether combining light therapy (phototherapy) with a targeted antibody drug called POTELIGEO can help control early-stage mycosis fungoides, a rare type of skin lymphoma. About 20 adults with stage IA-IIA disease will receive both treatments together. The main g…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
New pill takes on rare skin cancer in early trial
Disease control OngoingThis early-phase study tests a new drug called tulmimetostat (DZR123) in 24 adults with advanced mycosis fungoides or Sézary syndrome—rare types of skin lymphoma—who have already tried at least one other treatment. The main goals are to check the drug's safety and find the best d…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
Promising skin lymphoma trial withdrawn before starting
Disease control TerminatedThis study was designed to test a new drug called Resimmune against an oral medication (Zolinza) for people with a rare type of skin lymphoma called mycosis fungoides. The goal was to see if a single four-day treatment could completely clear the skin lesions. However, the trial w…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Promising combo targets rare skin cancer
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and gemcitabine, can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome—rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one other treatment. Researchers ar…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:47 UTC